红细胞分布宽度对非小细胞肺癌患者的临床价值被引量：3

Clinical Value of Red Blood Cell Distribution Width in Patients with Non-small Cell Lung Cancer

下载PDF

导出

摘要目的探讨非小细胞肺癌患者外周静脉血中红细胞分布宽度(RDW)在临床中的应用价值。方法将非小细胞肺癌患者246例,根据分期、淋巴结转移程度的不同分别对非小细胞肺癌患者进行分组,比较不同组间RDW的水平差异。应用SPSS24.0软件,所获数据采用Mann-Whitney U检验。结果不同分期的非小细胞肺癌患者中,Ⅰ期组全血RDW水平11.9%与Ⅱ期组12.1%相比,P>0.5,与Ⅲ期组12.9%、Ⅳ期组13.6%比较,P均<0.05;Ⅱ期组全血RDW水平与Ⅲ期、Ⅳ期组比较,均P<0.05;Ⅳ期组全血RDW水平高于期Ⅲ组,P<0.05;Ⅲ期和Ⅳ期组全血RDW水平13.4%显著高于Ⅰ期和Ⅱ期组12.0%,P<0.05。淋巴结转移程度不同的患者中,N0组全血RDW水平12.0%与N1组12.1%相比,P>0.5,与N2组13.1%、N3组13.7%比较,均P<0.05;N1组全血RDW水平与N2、N3组比较,均P<0.05;N3组全血RDW水平高于N2组,P<0.05。结论 RDW可作为非小细胞肺癌患者临床诊断及病情评估的指标。 Objective To explore the application value of red blood cell distribution width（RDW） of peripheral venous blood in patients with non-small cell lung cancer. Methods Medical records and RDW date of 246 patients with non-small cell lung cancer were collected from September 2012 to March 2015 in Shandong Qianfoshan Hospital. Patients with non-small cell lung cancer were divided into different groups according to disease stage and lymph node metastasis degree. Mann-Whitney U test was applied to compare the RDW differences among different groups. Results According to different stages, the comparison of RDW level in stage Ⅰ group （11.9%） with the RDW level in stage Ⅱ group （12.1%） was P〉0.05. RDW level in stage Ⅰ group was compared with that in stage Ⅲ （12.9%）group and stage Ⅳ （13.6%） group with P 〈 0.05. RDW level in stageⅡ group was compared with that in stage Ⅲ group and stage Ⅳ group with P 〈 0.05. The RDW levels in stage Ⅳ group was higher than that of in stage Ⅲ group, P 〈 0.05. RDW levels in stage Ⅲ group and stage Ⅳ group （13.4%） were higher than those in stage I group and Ⅱ group （12.0%）, P 〈 0.05. According to the degree of lymph node metastasis, the RDW level in NO group （12.0%） was compared with that of in N1 group （12.0%） with P〉0.05. The RDW level in NO group was compared with those of in N2 group （13.1%） and N3 group （13.7%） with P 〈 0.05. The RDW level in N1 group was compared with those of in N2 group and N3 group with P 〈 0.05. The RDW levels in N3 group was higher than those of in N2 group （P 〈 0.05）. Conclusion RDW can be considered as an indicator of clinical diagnosis and assessment of non-small cell lung cancer patients.

作者任昆仑臧琦 Ren Kunlun;Zang Qi(Weifang Medical University, Weifang 261053, Shandong;Shandong Qianfoshan Hospital, Jinan 250014, Shandong)

机构地区潍坊医学院山东省千佛山医院

出处《菏泽医学专科学校学报》 2018年第1期43-45,共3页 Journal of Heze Medical College

关键词非小细胞肺癌红细胞分布宽度淋巴结转移 Non-small cell lung cancer Red cell distribution width Lymphatic metastasis

分类号 R734.2 [医药卫生—肿瘤]

引文网络
相关文献

参考文献3

1王文,聂希会,王寿强,任兆增.非小细胞肺癌的维持治疗[J].菏泽医学专科学校学报,2016,28(2):81-82. 被引量：4
2牛光领.肺癌合并糖尿病27例外科治疗体会[J].菏泽医学专科学校学报,2015,27(3):58-58. 被引量：1
3万永伦,高倩萍.红细胞分布宽度与心血管疾病之间的病理生理联系[J].心血管病学进展,2016,37(4):387-390. 被引量：11

二级参考文献51

1简朝凤,王莉,卢敏,等.肺癌合并糖尿病10例临床分析[J].中外健康文摘,2012,9:232.
2何磊,魏庆民.红细胞分布宽度的临床应用新进展[J].医学综述,2013,19(1):135-137.
3Hemminki K, liX, Sundquist j, et al. Risk of cancer forlowing hospi- tation for type 2 diabetes[J]. Oneologist, 2010, 15(6): 548-555.
4Goidie JH, Coldman AJ.A mathematical model for relating the drug- Sensitivity of tumors to theirs spontaneous mutation rate[J].Cancer- TreatRep[J], 1979,63(11-12):1727.
5Day RS.Treatment sequencing, asymmetry, and uncertainty: protocol strategies for combination chemotherapy[J].Cancer Res, 1986.46: 3876-3885.
6Smith IE, O' Brien ME, Talbot DC, et al.Duration of chemotherapy in advanced non small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin[J].J Clin Oncology, 2001,19 : 1336-1343.
7Socinski MA, Schell M J, Peterman A, et al.Phase Ⅲ trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage Ⅲ B/Ⅳ non-small-cell lung cancer[J].J Clin Oncology, 2002,20:1335-1343.
8Yon Plessen C, Bergman B, Andresen O, et al.Palliative chemothera- py beyond three courses conveys no survival or consistent quality-of- life benefits in advanced non.-small,-cell lung cancer[J].Br J Can- cer, 2006,95: 966-973.
9Granovetter M, Maintenance therapy improves survival of NSCLC pa- tients[J].Lancet Oncology, 2013,14(9):e347.
10Kerbel RS, Klement G, Pritchard KI, et al.Continuous low-dose anti-angiogenic/metronomic chemotherapy from the research laboratory into the oneology elinic[J]. Ann Oncol, 2002,13(1): 12-15.